InspireMD Closes $25 Million Underwritten Public Offering
TEL AVIV, Israel, April 16, 2013 /PRNewswire/ –
InspireMD, Inc. (“InspireMD” or the “Company”) (NYSE MKT: NSPR) announced the closing
of an underwritten public offering of 12.5 million shares of its common stock at a price
to the public of $2.00 per share. The Company received net proceeds of approximately $22.6
million, after deducting underwriting discounts and commissions and other offering-related
costs. InspireMD granted the underwriters a 30-day option to purchase up to an additional
1.875 million shares to cover over-allotments, if any.
The Company intends to use a portion of the proceeds from the offering to assist in
retiring its convertible debentures, to support the worldwide commercialization of the
MGuard[TM] Coronary and Carotid Embolic Protection Stents (EPS), to pursue FDA approval in
the United States, and for general corporate purposes. Following this offering, the
Company will not have any indebtedness for borrowed money outstanding.
Cowen and Company, LLC was sole book runner and JMP Securities acted as co-lead
The offering of these securities were made only by means of a prospectus. A
registration statement relating to these securities has been declared effective by the
Securities and Exchange Commission (SEC). The registration statement may be accessed
through the SEC’s website at http://www.sec.gov.
A prospectus relating to these securities may be obtained from Cowen and Company, LLC
(c/o Broadridge Financial Services) at 1155 Long Island Avenue, Edgewood, NY, 11717, Attn:
Prospectus Department, or by calling (631) 274-2806.
This press release shall not constitute an offer to sell or a solicitation of an offer
to buy, nor shall there be any sale of these securities in any state or jurisdiction in
which such an offer, solicitation or sale would be unlawful prior to registration or
qualification under the securities laws of any such state or jurisdiction.
About InspireMD, Inc.
InspireMD is a medical device company focusing on the development and
commercialization of its proprietary stent system technology, MGuard(TM). InspireMD
intends to pursue applications of this technology in coronary, carotid and peripheral
artery procedures. InspireMD’s common stock is quoted on the NYSE MKT under the ticker
This press release contains “forward-looking statements.” Such statements may be
preceded by the words “intends,” “may,” “will,” “plans,” “expects,” “anticipates,”
“projects,” “predicts,” “estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward-looking statements are not guarantees of future performance, are based on
certain assumptions and are subject to various known and unknown risks and uncertainties,
many of which are beyond the Company’s control, and cannot be predicted or quantified and
consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, without limitation,
risks and uncertainties associated with (i) market acceptance of our existing and new
products, (ii) negative clinical trial results or lengthy product delays in key markets,
(iii) an inability to secure regulatory approvals for the sale of our products, (iv)
intense competition in the medical device industry from much larger, multi-national
companies, (v) product liability claims, (vi) our limited manufacturing capabilities and
reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement
by governmental and other third party payers for our products, (viii) our efforts to
successfully obtain and maintain intellectual property protection covering our products,
which may not be successful, (ix) legislative or regulatory reform of the healthcare
system in both the U.S. and foreign jurisdictions, (x) our reliance on single suppliers
for certain product components, (xi) the fact that we will need to raise additional
capital to meet our business requirements in the future and that such capital raising may
be costly, dilutive or difficult to obtain and (xii) the fact that we conduct business in
multiple foreign jurisdictions, exposing us to foreign currency exchange rate
fluctuations, logistical and communications challenges, burdens and costs of compliance
with foreign laws and political and economic instability in each jurisdiction. More
detailed information about the Company and the risk factors that may affect the
realization of forward-looking statements is set forth in the Company’s filings with the
Securities and Exchange Commission (SEC), including the Company’s Transition Report on
Form 10-K/T and its Quarterly Reports on Form 10-Q. Investors and security holders are
urged to read these documents free of charge on the SEC’s web site at
http://www.sec.gov. The Company assumes no obligation to publicly update or revise its
forward-looking statements as a result of new information, future events or otherwise.
For additional information:
InspireMD Desk Redington, Inc. +1-212-926-1733 +1-203-222-7399 firstname.lastname@example.org
SOURCE InspireMD, Inc.